Targeting vessels to treat hepatocellular carcinoma
- PMID: 18302534
- DOI: 10.1042/CS20070310
Targeting vessels to treat hepatocellular carcinoma
Abstract
The process of blood vessel proliferation, known as angiogenesis, is essential during embryonic development and organogenesis. In adult life, it participates in normal tissue repair, wound healing, and cyclical growth of the corpus luteum and the endometrium. Crucial as it is, angiogenesis can become pathological, and abnormal angiogenesis contributes to the pathogenesis of inflammatory and neoplasic diseases. The present review highlights the evidence for the role of angiogenesis in HCC (hepatocellular carcinoma) and discusses the increasing importance of inhibitors of angiogenesis in HCC therapy.
Similar articles
-
From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now.Oncology. 2007;72 Suppl 1:30-44. doi: 10.1159/000111705. Epub 2007 Dec 13. Oncology. 2007. PMID: 18087180 Review.
-
Antiangiogenic strategies in hepatocellular carcinoma: current status.Expert Rev Anticancer Ther. 2005 Aug;5(4):645-56. doi: 10.1586/14737140.5.4.645. Expert Rev Anticancer Ther. 2005. PMID: 16111465 Review.
-
Angiogenesis blockade as therapy for hepatocellular carcinoma: progress and challenges.J Gastroenterol Hepatol. 2011 Jan;26(1):4-6. doi: 10.1111/j.1440-1746.2010.06590.x. J Gastroenterol Hepatol. 2011. PMID: 21175786 No abstract available.
-
Vascular changes in hepatocellular carcinoma.Anat Rec (Hoboken). 2008 Jun;291(6):721-34. doi: 10.1002/ar.20668. Anat Rec (Hoboken). 2008. PMID: 18484619 Review.
-
Angiogenesis and anti-angiogenesis in hepatocellular carcinoma.Cancer Treat Rev. 2006 Oct;32(6):437-44. doi: 10.1016/j.ctrv.2006.06.002. Epub 2006 Jul 25. Cancer Treat Rev. 2006. PMID: 16870349 Review.
Cited by
-
Overcoming the therapeutic resistance of hepatomas by targeting the tumor microenvironment.Front Oncol. 2022 Nov 15;12:988956. doi: 10.3389/fonc.2022.988956. eCollection 2022. Front Oncol. 2022. PMID: 36457492 Free PMC article. Review.
-
Liver fatty acid-binding protein (L-FABP) promotes cellular angiogenesis and migration in hepatocellular carcinoma.Oncotarget. 2016 Apr 5;7(14):18229-46. doi: 10.18632/oncotarget.7571. Oncotarget. 2016. PMID: 26919097 Free PMC article.
-
Combination of sorafenib and angiotensin-II receptor blocker attenuates preneoplastic lesion development in a non-diabetic rat model of steatohepatitis.J Gastroenterol. 2014 Oct;49(10):1421-9. doi: 10.1007/s00535-013-0906-y. Epub 2013 Nov 7. J Gastroenterol. 2014. PMID: 24197250
-
Genome-wide CRISPR Screening Identifies NFκB and c-MET as Druggable Targets to Sensitize Lenvatinib Treatment in Hepatocellular Carcinoma.Cell Mol Gastroenterol Hepatol. 2025;19(7):101502. doi: 10.1016/j.jcmgh.2025.101502. Epub 2025 Mar 20. Cell Mol Gastroenterol Hepatol. 2025. PMID: 40120675 Free PMC article.
-
Roles of the Dynamic Tumor Immune Microenvironment in the Individualized Treatment of Advanced Clear Cell Renal Cell Carcinoma.Front Immunol. 2021 Mar 4;12:653358. doi: 10.3389/fimmu.2021.653358. eCollection 2021. Front Immunol. 2021. PMID: 33746989 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical